FDA Inspection 1330724 — Eversight
The FDA completed an inspection of Eversight on Jul 29, 2026 in Cleveland, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 29, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Cleveland, OH (United States)